1
|
Chi Z, Wang Q, Tong L, Qiu J, Yang F, Guo Q, Li W, Zheng J, Chen Z. Silencing geranylgeranyltransferase I inhibits the migration and invasion of salivary adenoid cystic carcinoma through RhoA/ROCK1/MLC signaling and suppresses proliferation through cell cycle regulation. Cell Biol Int 2024; 48:174-189. [PMID: 37853939 DOI: 10.1002/cbin.12096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 09/05/2023] [Accepted: 09/30/2023] [Indexed: 10/20/2023]
Abstract
Geranylgeranyltransferase type I (GGTase-I) significantly affects Rho proteins, such that the malignant progression of several cancers may be induced. Nevertheless, the effect and underlying mechanism of GGTase-I in the malignant progression of salivary adenoid cystic carcinoma (SACC) remain unclear. This study primarily aimed to investigate the role and mechanism of GGTase-I in mediating the malignant progression of SACC. The level of GGTase-I gene in cells was stably knocked down by short hairpin RNA-EGFP-lentivirus. The effects of GGTase-I silencing on the migration, invasion, and spread of cells were examined, the messenger RNA levels of GGTase-I and RhoA genes of SACC cells after GGTase-I knockdown were determined, and the protein levels of RhoA and RhoA membrane of SACC cells were analyzed. Moreover, the potential underlying mechanism of silencing GGTase-I on the above-mentioned aspects in SACC cells was assessed by examining the protein expression of ROCK1, MLC, p-MLC, E-cadherin, Vimentin, MMP2, and MMP9. Furthermore, the underlying mechanism of SACC cells proliferation was investigated through the analysis of the expression of cyclinD1, MYC, E2F1, and p21CIP1/WAF1 . Besides, the change of RhoA level in SACC tissues compared with normal paracancer tissues was demonstrated through quantitative reverse-transcription polymerase chain reaction and western blot experiments. Next, the effect after GGTase-I silencing was assessed through the subcutaneous tumorigenicity assay. As indicated by the result of this study, the silencing of GGTase-I significantly reduced the malignant progression of tumors in vivo while decreasing the migration, invasion, and proliferation of SACC cells and RhoA membrane, Vimentin, ROCK1, p-MLC, MMP2, MMP9, MYC, E2F1, and CyclinD1 expression. However, the protein expression of E-cadherin and p21CIP1/WAF1 was notably upregulated. Subsequently, no significant transform of RhoA and MLC proteins was identified. Furthermore, RhoA expression in SACC tissues was significantly higher than that in paracancerous tissues. As revealed by the results of this study, GGTase-I shows a correlation with the proliferation of SACC through the regulation of cell cycle and may take on vital significance in the migration and invasion of SACC by regulating RhoA/ROCK1/MLC signaling pathway. GGTase-I is expected to serve as a novel exploration site of SACC.
Collapse
Affiliation(s)
- Zengpeng Chi
- Department of Stomatology, Qingdao West Coast New District Central Hospital, Qingdao, China
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Qimin Wang
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Lei Tong
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Jing Qiu
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Fang Yang
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Qingyuan Guo
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Wenjian Li
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| | - Jiawei Zheng
- Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zhenggang Chen
- Department of Stomatology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
| |
Collapse
|
2
|
Lian B, Li Z, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Sheng X, Tian H, Si L, Chi Z, Wang X, Lai Y, Sun T, Zhang Q, Kong Y, Long GV, Guo J, Cui C. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol 2024; 35:211-220. [PMID: 37956739 DOI: 10.1016/j.annonc.2023.10.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 10/16/2023] [Accepted: 10/19/2023] [Indexed: 11/15/2023] Open
Abstract
BACKGROUND The outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial. It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we conducted this trial. PATIENTS AND METHODS This single-arm phase II trial enrolled patients with resectable mucosal melanoma. Patients received toripalimab 3 mg/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.) for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg/kg Q2W starting 2 ± 1weeks after surgery for 44 weeks. The primary endpoint was the pathologic response rate according to the International Neoadjuvant Melanoma Consortium recommendations. RESULTS Between August 2019 and October 2021, 29 patients were enrolled and received treatment, of whom 24 underwent resection. The median follow-up time was 34.2 months (95% confidence interval 20.4-48.0 months). The pathologic response rate was 33.3% (8/24; 4 pathological complete responses and 4 pathological partial responses). The median event-free survival for all patients was 11.1 months (95% confidence interval 5.3-16.9 months). The median overall survival was not reached. Neoadjuvant therapy was tolerable with 8 (27.5%) grade 3-4 treatment-related adverse events and no treatment-related deaths. Tissue samples of 17 patients at baseline and after surgery were collected (5 responders and 12 nonresponders). Multiplex immunohistochemistry demonstrated a significant increase in CD3+ (P = 0.0032) and CD3+CD8+ (P = 0.0038) tumor-infiltrating lymphocytes after neoadjuvant therapy, particularly in pathological responders. CONCLUSIONS Neoadjuvant toripalimab combined with axitinib in resectable mucosal melanoma demonstrated a promising pathologic response rate with significantly increased infiltrating CD3+ and CD3+CD8+ T cells after therapy.
Collapse
Affiliation(s)
- B Lian
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Z Li
- Department of Pathology, Peking University Cancer Hospital and Institute, Beijing
| | - N Wu
- Department of Thoracic Surgery, Peking University Cancer Hospital and Institute, Beijing
| | - M Li
- Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing
| | - X Chen
- Department of Otorhinolaryngology, Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing
| | - H Zheng
- Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing
| | - M Gao
- Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing
| | - D Wang
- Peking University School of Stomatology, Beijing
| | - X Sheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - H Tian
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - L Si
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Z Chi
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - X Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Y Lai
- Department of Pathology, Peking University Cancer Hospital and Institute, Beijing
| | - T Sun
- The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China
| | - Q Zhang
- The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China
| | - Y Kong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - G V Long
- Melanoma Institute of Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - C Cui
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
| |
Collapse
|
3
|
Hong X, Zhang Y, Chi Z, Xu Q, Lin W, Huang Y, Lin T, Zhang Y. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol) 2024; 36:e20-e30. [PMID: 37993317 DOI: 10.1016/j.clon.2023.11.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 09/14/2023] [Accepted: 11/13/2023] [Indexed: 11/24/2023]
Abstract
AIMS The aim of this systematic review with meta-analysis was to evaluate the efficacy and safety of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS We searched PubMed, Embase and Cochrane Library until 1 July 2022 for mCRPC trials testing PD-1/PD-L1 checkpoint inhibitors. We measured the efficacy and safety using overall survival, progression-free survival (PFS), overall response rates (ORR), prostate-specific antigen (PSA) response rate or treatment-related adverse events (TRAEs). When possible, data were meta-analysed. RESULTS Thirteen studies involving 2533 participants were included in this meta-analysis. The pooled hazard ratio for overall survival was 0.81 (95% confidence interval 0.42-1.20, I2 = 80.3%, PHeterogeneity<0.001) and for PFS was 0.65 (95% confidence interval 0.38-0.92, I2 = 72.2%, PHeterogeneity = 0.013). Furthermore, better ORR (relative risk = 2.77, 95% confidence interval 1.25-6.13, I2 = 0%, PHeterogeneity = 0.699) was found in PD-L1-expressing tumours. However, no statistical trends between PD-L1 status on PSA response rate (relative risk = 0.79, 95% confidence interval 0.5-1.25, I2 = 0%, PHeterogeneity = 0.953) and tumour mutational burden on ORR (relative risk = 2.53, 95% confidence interval 0.49-13.12, I2 = 74.5%, PHeterogeneity = 0.02) were observed. The pooled proportions of TRAEs and ≥ grade 3 TRAEs were 85.1% (95% confidence interval = 71.7-98.5%) and 31.6% (95% confidence interval = 18.9-44.4%), respectively. CONCLUSIONS This meta-analysis showed that among selected populations of men with mCRPC, anti-PD-1/PD-L1 combination treatment may significantly increase the PFS benefits. However, overall survival in mCRPC warrants further testing.
Collapse
Affiliation(s)
- X Hong
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China; Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - Y Zhang
- Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - Z Chi
- Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - Q Xu
- Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - W Lin
- Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - Y Huang
- Department of Urology, Shantou Central Hospital, Shantou, PR China
| | - T Lin
- Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China.
| | - Y Zhang
- Department of Urology, Shantou Central Hospital, Shantou, PR China.
| |
Collapse
|
4
|
Zhan-Qiang H, Hai-Hua Q, Chi Z, Miao W, Cui Z, Zi-Yin L, Jing H, Yi-Wei W. miR-146a aggravates cognitive impairment and Alzheimer disease-like pathology by triggering oxidative stress through MAPK signaling. Neurologia 2023; 38:486-494. [PMID: 37659839 DOI: 10.1016/j.nrleng.2020.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 12/26/2020] [Indexed: 09/04/2023] Open
Abstract
INTRODUCTION Mir-146a-5p has been widely recognized as a critical regulatory element in the immune response. However, recent studies have shown that miR-146a-5p may also be involved in the development of Alzheimer disease (AD). Regrettably, the related mechanisms are poorly understood. Here, we investigated the effects of miR-146a in mice models and SH-SY5Y cells treated with amyloid β (Aβ)1-42. METHODS To create a model of AD, SH-SY5Y cells were treated with Aβ1-42 and mice received intracerebroventricular injections of Aβ1-42. Then, the transcriptional levels of miR-146a were estimated by real-time PCR. We transiently transfected the miR-146a-5p mimic/inhibitor into cells and mice to study the role of miR-146a. The role of signaling pathways including p38 and reactive oxygen species (ROS) was studied by using specific inhibitors. Aβ and amyloid-beta precursor protein (APP)levels were measured by immunoblotting. Furthermore, Aβ expression was analyzed by immunofluorescence and histochemical examinations. RESULTS Aβ1-42-stimulated SH-SY5Y cells displayed increased transcriptional levels of miR-146a and APP. Moreover, the p38 MAPK signaling pathway and ROS production were activated upon stimulation with a miR-146a-5p mimic. However, treatment with a miR-146a-5p inhibitor decreased the levels of APP, ROS, and p-p38 MAPK. A similar phenomenon was also observed in the animals treated with Aβ1-42, in which miR-146a upregulation increased the expression of Aβ, p-p38, and ROS, while the inhibition of miR-146a had the opposite effect. This suggests that miR-146a increases Aβ deposition and ROS accumulation via the p-p38 signaling pathway. CONCLUSIONS Our research demonstrates that miR-146a-5pa increases Aβ deposition by triggering oxidative stress through activation of MAPK signaling.
Collapse
Affiliation(s)
- H Zhan-Qiang
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Q Hai-Hua
- Department of Dermatology, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Z Chi
- Department of Neurology, Affilicated Hospital of Chengde Medical College, Chengde 067000, China
| | - W Miao
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Z Cui
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - L Zi-Yin
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - H Jing
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - W Yi-Wei
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
| |
Collapse
|
5
|
Yang Y, Lian B, Si L, Chi Z, Sheng X, Kong Y, Cui CL, Guo J. 851P Frequency and clinical significance of homologous recombination deficiency gene mutations in non-cutaneous melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Lian B, Yang Y, Si L, Zhou L, Chi Z, Sheng X, Mao L, Wang X, Cui CL, Zheng B, Guo J. 808P Postoperative adjuvant radiotherapy can reduce the local recurrence of nasal cavity and paranasal sinus mucosal melanoma: A prospective design, retrospective analysis and case–control study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Wei X, Wang X, Bai X, Li C, Mao L, Chi Z, Lian B, Bixia T, Kong Y, Dai J, Andtbacka R, Guo J, Cui CL, Si L. 795P A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
8
|
Cui CL, Li Z, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Lian B, Wang X, Tian H, Si L, Chi Z, Sheng X, Lai Y, Sun T, Zhang Q, Kong Y, Guo J. 796P Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Si L, Qi Z, Dai J, Bai X, Mao L, Li C, Wei X, Cui CL, Chi Z, Sheng X, Kong Y, Bixia T, Zhou L, Lian B, Wang X, Duan R, Guo J. 815P A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Wang X, Wu W, Wu X, Si L, Chi Z, Sheng X, Li L, Han W, Li H, Lian B, Zhou L, Mao L, Bai X, Bixia T, Wei X, Cui CL, Kong Y, Guo J. 879P Whole-genome landscape of head and neck melanomas in East Asia (China). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Lian B, Cui C, Si L, Chi Z, Sheng X, Mao L, Wang X, Tang B, Bai X, Yan X, Li S, Zhou L, Zhou H, Wang Y, Hou QS, Guo J. 1086P IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Lv MY, He D, Lin Y, Chen Z, Chen J, Chi Z, Huang T, Chen X, He X. 504P Prognostic factors of patients with AFP-positive colorectal cancer: A case-control study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Zhan-Qiang H, Hai-Hua Q, Chi Z, Miao W, Cui Z, Zi-Yin L, Jing H, Yi-Wei W. miR-146a aggravates cognitive impairment and Alzheimer disease-like pathology by triggering oxidative stress through MAPK signaling. Neurologia 2021; 38:S0213-4853(21)00022-0. [PMID: 33715884 DOI: 10.1016/j.nrl.2020.12.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 12/14/2020] [Accepted: 12/26/2020] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Mir-146a-5p has been widely recognized as a critical regulatory element in the immune response. However, recent studies have shown that miR-146a-5p may also be involved in the development of Alzheimer disease (AD). Regrettably, the related mechanisms are poorly understood. Here, we investigated the effects of miR-146a in mice models and SH-SY5Y cells treated with amyloid β (Aβ)1-42. METHODS To create a model of AD, SH-SY5Y cells were treated with Aβ1-42 and mice received intracerebroventricular injections of Aβ1-42. Then, the transcriptional levels of miR-146a were estimated by real-time PCR. We transiently transfected the miR-146a-5p mimic/inhibitor into cells and mice to study the role of miR-146a. The role of signaling pathways including p38 and reactive oxygen species (ROS) was studied by using specific inhibitors. Aβ and amyloid-beta precursor protein (APP)levels were measured by immunoblotting. Furthermore, Aβ expression was analyzed by immunofluorescence and histochemical examinations. RESULTS Aβ1-42-stimulated SH-SY5Y cells displayed increased transcriptional levels of miR-146a and APP. Moreover, the p38 MAPK signaling pathway and ROS production were activated upon stimulation with a miR-146a-5p mimic. However, treatment with a miR-146a-5p inhibitor decreased the levels of APP, ROS, and p-p38 MAPK. A similar phenomenon was also observed in the animals treated with Aβ1-42, in which miR-146a upregulation increased the expression of Aβ, p-p38, and ROS, while the inhibition of miR-146a had the opposite effect. This suggests that miR-146a increases Aβ deposition and ROS accumulation via the p-p38 signaling pathway. CONCLUSIONS Our research demonstrates that miR-146a-5pa increases Aβ deposition by triggering oxidative stress through activation of MAPK signaling.
Collapse
Affiliation(s)
- H Zhan-Qiang
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Q Hai-Hua
- Department of Dermatology, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Z Chi
- Department of Neurology, Affilicated Hospital of Chengde Medical College, Chengde 067000, China
| | - W Miao
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - Z Cui
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - L Zi-Yin
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - H Jing
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China
| | - W Yi-Wei
- Department of General medicine, Affiliated Hospital of Chengde Medical College, Chengde 067000, China.
| |
Collapse
|
14
|
Su ZH, Liao HH, Lu KE, Chi Z, Qiu ZQ, Jiang JM, Wu Z. Hypoxia-responsive miR-346 promotes proliferation, migration, and invasion of renal cell carcinoma cells via targeting NDRG2. Neoplasma 2020; 67:1002-1011. [DOI: 10.4149/neo_2020_190917n915] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 01/07/2020] [Indexed: 11/08/2022]
|
15
|
Si L, Mao L, Zhou L, Li C, Wang X, Cui C, Sheng X, Chi Z, Lian B, Tang B, Yan X, Li S, Bai X, Dai J, Kong Y, Lin L, Zhang J, Wu Z, Hui A, Guo J. A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Dai J, Si L, Cui C, Sheng X, Kong Y, Chi Z, Mao L, Wang X, Lian B, Li S, Yan X, Tang B, Bai X, Zhou L, Guo J. Genomic landscape of primary malignant melanoma of esophagus. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Mingchang M, Ma W, Zhang R, Chi Z. EP-1864 Dose optimization research of esophageal cancer with automatic treatment planning module. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32284-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
18
|
Cui C, Yan X, Liu S, Deitz A, Si L, Chi Z, Sheng X, Lian B, Li J, Ge J, Wang X, Mao L, Tang B, Zhou L, Bai X, Li S, Li B, Wu H, Guo J. Treatment pattern and clinical outcomes of patients with locally advanced and metastatic melanoma in a real-world setting in China. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Wang X, Cui C, Yu J, Kong Y, Si L, Chi Z, Sheng X, Mao L, Lian B, Tang B, Yan X, Guo J. Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Mao L, Wang X, Si L, Kong Y, Chi Z, Sheng X, Cui C, Lian B, Tang B, Yan X, Guo J. The use of PD-1 inhibitors for the advanced melanoma of esophagus. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Cui C, Lian B, Chi Z, Si L, Sheng X, Bixia T, Mao L, Wang X, Yan X, Li S, Zhou L, Bai X, Guo J. Phase Ic trial of intralesional OrienX010 oncolytic viral therapy into liver metastases among melanoma patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Mao L, Si L, Bai X, Chi Z, Cui C, Sheng X, Lian B, Bixia T, Yan X, Guo J. Choice of adjuvant therapy in uveal melanoma: A retrospective analysis in China. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Wang Y, Jia SJ, Chi Z. [Relationship between the ratio of neutrophil/lymphocyte and risk stratification, prognosis in patients with non-ST-elevation acute coronary syndrome]. Zhonghua Yi Xue Za Zhi 2017. [PMID: 28647999 DOI: 10.3760/cma.j.issn.0376-2491.2017.23.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the value of neutrophil to lymphocyte ratio (NLR) in predicting risk stratification and prognosis in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). Methods: A total of 227 NSTE-ACS patients after percutaneous coronary intervention (PCI) were collected from September 2012 to September 2014 in Beijing Anzhen Hospital.Groups: (1)According to NLR, the patients were divided into 3 groups: NLR<2.20 group; 2.2≤NLR<3.33 group; NLR≥3.33 group.(2)According to the global registry of acute coronary events (GRACE) score, the patients were divided into 3 groups: Low-risk group, Medium-risk group and High-risk group.(3)According to the occurrence of major adverse cardiac events (MACE), the patients were divided into 2 groups: MACE group and non MACE group.Receiver operator characteristic curve (ROC) was used to assess value of NLR for high risk NSTE-ACS patients.Then COX regression analysis was used to analyze correlation between NLR and MACE. Results: A total of 227 NSTE-ACS patients after PCI were collected and the ratio of MACE was 32.2% (73/227). The GRACE score and the incidence of MACE in NLR≥3.33 group were higher than those in 2.2≤NLR<3.33 group and NLR<2.20 group (all P<0.01). The level of NLR and the incidence of MACE in High-risk group were higher than those in Low-risk group and Medium-risk group (all P<0.05). The level of NLR and the GRACE score in MACE group were higher than those in non MACE group (all P<0.05). COX regression analysis indicated that NLR was independent risk factor for MACE occurrence in NSTE-ACS patients at 1 year after PCI (OR=1.214, 95%CI: 1.114-1.323, P=0.000). Conclusion: The level of NLR has significant correlation with High-risk NSTE-ACS patients, and NLR is an independent risk factor for poor prognosis in patients with NSTE-ACS.
Collapse
Affiliation(s)
- Y Wang
- Department of VIP, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
| | | | | |
Collapse
|
24
|
Lian B, Cui C, Zhou L, Song X, Zhang X, Wu D, Si L, Chi Z, Sheng X, Balch C, Guo J. 404O The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw589.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Liu D, Chi Z, Yang H, Miao M, Jing Z. SU-E-P-48: Evaluation of Intensity Modulated Radiotherapy (IMRT) with Three Different Commercial Planning Systems for the Treatment of Cervical Cancer. Med Phys 2015. [DOI: 10.1118/1.4923982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
Qiu R, Wang Y, Chi Z. SU-E-T-740: The Optimization in Segment Numbers for Nasopharyngeal Carcinoma (NPC) Treated by Intensity Modulated. Med Phys 2015. [DOI: 10.1118/1.4925104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Zhang R, Bai W, Gao Y, Chi Z, Gao C, Xiaomei F. SU-E-P-55: The Reaserch of Cervical Cancer Delivered with Constant Dose Rate and Gantry Speed Arc Therapy(CDR-CAS-IMAT) On Conventional Linac. Med Phys 2015. [DOI: 10.1118/1.4923989] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Zhang R, Bai W, Xiaomei F, Chi Z, Runxiao L, Ren Q, Gao C. SU-E-P-39: Characterization of Dose Impact On Different Beam Fields Size Attenuation for Elekta IGRT Couch. Med Phys 2015. [DOI: 10.1118/1.4923973] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
cao Y, Li R, Chi Z, Zhu S. SU-E-T-580: Comparison of Cervical Carcinoma IMRT Plans From Four Commercial Treatment Planning Systems (TPS). Med Phys 2014. [DOI: 10.1118/1.4888916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Shang K, Wang J, Liu D, Li R, Cao Y, Chi Z. SU-E-J-248: Comparative Study of Two Image Registration for Image-Guided Radiation Therapy in Esophageal Cancer. Med Phys 2014. [DOI: 10.1118/1.4888302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
31
|
cao Y, Li R, Chi Z. SU-E-T-608: Performance Comparison of Four Commercial Treatment Planning Systems Applied to Intensity-Modulated Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4888944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Chi Z, Li R, qiu R, cao Y, Han C. SU-E-T-39: Analyses of Plan Quality Using Different Gantry Rotation Time On Volumetric Modulated Arc Therapy in Rectal Carcinoma. Med Phys 2014. [DOI: 10.1118/1.4888369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Li R, cao Y, Shang K, Wang J, Zhang R, Jing Z, Han C, Chi Z. SU-E-T-643: A Comparison of the DTA and Gamma Index Analysis for IMRT/VMAT Plans in Rectal Carcinoma. Med Phys 2014. [DOI: 10.1118/1.4888979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Qiu R, Wang Y, Cao Y, Zhang R, Shang K, Chi Z. SU-E-T-592: Relationship Between Dose of Distribution and Area of Segment Fields Among Different Intensity-Modulated Radiotherapy Planning in Cervix Cancer. Med Phys 2014. [DOI: 10.1118/1.4888928] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Chi Z, Wang Z, Wang K, Zhu Y, Qin S. Cathelicidin Antimicrobial Peptide LL-37 in Cholesteatoma Enables Keratinocyte Reactivity with Cytosolic DNA. Scand J Immunol 2014; 79:214-21. [PMID: 24383796 DOI: 10.1111/sji.12149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 12/16/2013] [Indexed: 12/21/2022]
Affiliation(s)
- Z. Chi
- Department of Otolaryngology; Eye & ENT Hospital; Fudan University; Shanghai China
| | - Z. Wang
- Department of Otolaryngology; Eye & ENT Hospital; Fudan University; Shanghai China
| | - K. Wang
- Department of Otolaryngology; Eye & ENT Hospital; Fudan University; Shanghai China
| | - Y. Zhu
- Department of Otolaryngology; Eye & ENT Hospital; Fudan University; Shanghai China
| | - S. Qin
- Department of Otolaryngology; Eye & ENT Hospital; Fudan University; Shanghai China
| |
Collapse
|
36
|
Qiu X, Cao L, Yang X, Zhao X, Liu X, Han Y, Xue Y, Jiang H, Chi Z. Role of mitochondrial fission in neuronal injury in pilocarpine-induced epileptic rats. Neuroscience 2013; 245:157-65. [DOI: 10.1016/j.neuroscience.2013.04.019] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Revised: 03/18/2013] [Accepted: 04/03/2013] [Indexed: 12/18/2022]
|
37
|
Liu D, Chi Z, Gao C, Han C. SU-E-T-513: Evaluation Output Dose of Electron Beams Based On Monte Carlo. Med Phys 2013. [DOI: 10.1118/1.4814942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Shang K, Chi Z, Wang J. SU-E-J-210: Setup Error Effects of Different Cycles During Treatment Process of Esophageal Cancer Radiotherapy. Med Phys 2013. [DOI: 10.1118/1.4814422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Gao C, Chi Z, Liu D. SU-E-P-22: Study of Dose Calculation Using Monte Carlo Method in Radiotherapy. Med Phys 2013. [DOI: 10.1118/1.4814096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Gao C, Han C, Chi Z, Liu D. SU-E-T-712: Analyzing the Feasibility of the Margin From CTV to PTV for Esophageal Carcinoma with Retraction Method. Med Phys 2013. [DOI: 10.1118/1.4815139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
41
|
Cao Y, Gao C, Wang L, Chi Z, Han C. SU-E-J-124: Comparison of Infrared Marker-Based Positioning System and EPID for the Measurement of Setup Errors. Med Phys 2011. [DOI: 10.1118/1.3611892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Liu D, Chi Z, Cao Y, Li R, Han C. SU-E-T-855: The Correlation Analysis of IMRT Dosimetry Errors and Parameters of Beams. Med Phys 2011. [DOI: 10.1118/1.3612819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
43
|
Chi Z, Liu D, Cao Y, Han C. SU-E-T-716: An Investigation of Heterogeneity Dose Calculation Accuracy in IMRT from Five Commercial Treatment Planning Systems Useing Monte Carlo. Med Phys 2011. [DOI: 10.1118/1.3612678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
44
|
Cao Y, Chi Z, Li R, Han C, Zhu S. SU-E-T-857: Comparison of Nasopharyngeal Carcinoma IMRT Plans from Four Commercial Treatment Planning Systems (TPS). Med Phys 2011. [DOI: 10.1118/1.3612821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
45
|
Li Y, Chi Z, Liu D. SU-E-T-437: Dosimetry Study of Setup Errors in Intensity-Modulated Radiotherapy of Cervical Cancer Post-Surgery. Med Phys 2011. [DOI: 10.1118/1.3612391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
46
|
Wang L, Han C, Jie D, Chi Z. The Predictive Value of Basic Lung Function and Dosimetric Parameters to Acute Radiation Pneumonitis (ARP) during the Treatment of Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Liu D, Chi Z, Cao Y, Han C, Wang L. Evaluation Quality of IMRT Plans Based on Biological and Dose Cost Function. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Zhu S, Wang J, Han C, Chi Z, Wang Y, Liu J, Wang P, Chu L. Value of CT Scan, Esophagogram, and Endoscopy in Defining Tumor Length for the Thoracic Esophageal Carcinoma. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Han C, Wang L, Gao C, Li X, Chi Z. The Predictive Value of Low Dose Volume of Lung to Acute Radiation Pneumonitis in Thoracic Carcinoma Treatment using Three Dimensional Conformal Radiotherapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Zhang T, Chi Z, Zhao CH, Chi ZM, Gong F. Bioethanol production from hydrolysates of inulin and the tuber meal of Jerusalem artichoke by Saccharomyces sp. W0. Bioresour Technol 2010; 101:8166-70. [PMID: 20598527 DOI: 10.1016/j.biortech.2010.06.013] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2010] [Revised: 06/01/2010] [Accepted: 06/02/2010] [Indexed: 05/29/2023]
Abstract
It has been confirmed that Saccharomyces sp. W0 can produce high concentration of ethanol. However, this yeast strain cannot secrete inulinase. Therefore, in this study, inulin was hydrolyzed into reducing sugar by the recombinant inulinase produced by Pichia pastoris X-33/pPICZaA-INU1. It was found that 38.2U of the recombinant inulinase per gram of inulin was suitable for the inulin hydrolysis and ethanol production by Saccharomyces sp. W0 and the fermentation period was 120 h. At the end of the fermentation, over 14.6 ml of ethanol per 100ml of the fermented medium was produced, the ethanol productivity was over 0.384 g of ethanol/g of inulin and over 98.8% of total sugar was utilized. When the Saccharomyces sp. W0 was grown in the mixture of 4.0% hydrolysate of soybean meal and 20.0% of the hydrolysate of inulin for 120 h, over 14.9 ml of ethanol per 100ml of the fermented medium was yielded, the ethanol productivity was over 0.393 g of ethanol/g of inulin and 98.9% of total sugar was used by the yeast strain. When Saccharomyces sp. W0 carrying the same inulinase gene was grown in the medium containing 50 g of the tuber meal of Jerusalem artichoke per 100ml for 144 h, over 12.1+/-0.35%ml of ethanol per 100ml of the fermented medium was yielded, the ethanol productivity was 0.319+/-0.9 g of ethanol/g of sugar and 3.7% (w/v) of total sugar and 0.5% (w/v) of reducing sugar were left in the fermented media.
Collapse
Affiliation(s)
- T Zhang
- Unesco Chinese Center of Marine Biotechnology and Institute of Marine Biodiversity and Evolution, Ocean University of China, Yushan Road, No. 5. Qingdao, China
| | | | | | | | | |
Collapse
|